Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > National Bank Comments

<< Previous

Bullboard Posts

Next >>

Comment by juniper88on Oct 25, 2023 9:59pm

74 Views

Post# 35701364

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:National Bank Comments

My point was more like "buyer beware". They threw us under the bus (twice now), soleus (if they sold it was at a substantial loss), and Paul will have no loyalty for the next investor either.

And what is the point of laying off all those scientists if you're going to do this? The more I think about this the less sense it makes.